• Christian Lindholm Interim CEO / CFO since 2016.

    Christian Lindholm has during the last 17 years held positions as CFO within both private and listed companies. Prior to joining Acarix Christian was CFO at Doro AB and TFS International AB. Christian Lindholm has studied economy at University of Växjö and Kristianstad.

    Acarix shareholdings:
    Shares: 2.000
    Warrants: 25.500

    +46 705 118 333

  • Claus Bo Vöge Christensen Chief Operating Officer since 2009

    Claus Bo Vöge Christensen has experience from own research, including managing experience from research departments and research projects from start-up companies doing product- and business innovation through market- and user studies. At Acarix Claus Bo Vöge Christensen has partly been executing clinical studies and processes leading to CE-registration, and fully engaged in product development and production. Claus Bo Vöge Christensen has previous experience from Novozymes A/S, MIC-DTU and latest from Coloplast A/S, being responsible for ”Medical Monitoring & Diagnostics” from where Acarix A/S was initiated. Claus Bo Vöge Christensen has an MBA from The Technical University of Denmark and a PhD in Molecular biology from University of Copenhagen, Denmark.

    Shares: 154.982
    Warrants: 112.500

    +45 2972 4411

  • Dr. Anja Schaefer Chief Marketing Officer since 2016. (Engaged in Acarix through consultancy agreement.)

    Anja Schaefer has since 2014 been CEO of strategy consultancy company TaRes GmbH, Germany. She has more than 25 years experience in the health care industry including international leadership roles for pharmaceutical and medical device companies in various commercial and medical affairs functions. Anja succesfully launched innovative products and managed all live cicle stages for broad product portfolios with a focus on Cardiology since 1995. She holds a PhD in molecular genetics from The Max Planck Institute in Berlin, Germany.

    Acarix shareholdings:
    Shares: 2.500
    Warrants: 0


    +49 171 8343085